The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.
 
Yoshihiro Nishida
Honoraria - Astellas Pharma; Chugai Pharma; Daiichi Sankyo
Consulting or Advisory Role - Seikagaku
Research Funding - Novartis
 
Hiroshi Urakawa
No Relationships to Disclose
 
Robert Nakayama
No Relationships to Disclose
 
Toshifumi Ozaki
No Relationships to Disclose
 
Keisuke Ae
No Relationships to Disclose
 
Yoshihiro Matsumoto
Honoraria - Eisai
 
Yuichi Ando
Honoraria - AstraZeneca; Bayer Holding; Bristol-Myers Squibb; Celltrion; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; Nippon Kayaku; Novartis; Novartis; Ono Pharmaceutical; Otsuka; Roche; Sawai Pharmaceutical Co; Shionogi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - ICON Clinical Research; Ono Pharmaceutical; Sun Pharma; SymBio Pharmaceuticals
Research Funding - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
 
Yachiyo Kuwatsuka
No Relationships to Disclose
 
Takafumi Ueda
Consulting or Advisory Role - Daiichi Sankyo; Eisai; Otsuka
Research Funding - Eisai; Lilly Japan; Taiho Pharmaceutical; Takara Bio
 
Akira Kawai
Honoraria - Daiichi Sankyo; Eisai; Lilly; Novartis; Otsuka; Taiho Pharmaceutical; Takara Bio